Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prednisone plus thalidomide versus prednisone plus placebo for IgG4-related disease
ChiCTR2000028918Phase 4Recruiting
- Sponsor
- Tongji Hospital
- Start
- Jan 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of thalidomide and prednisone in IgG4-related disease (IgG4-RD) (2 arms), sponsored by Tongji Hospital. Primary endpoint: Recurrence rate. Started Jan 2020; status: recruiting.
02
Drugs
thalidomideprednisone
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on ChiCTR2000028918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000028918.